National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark.
Cancer Society of Finland, Finnish Cancer Registry - Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland.
Pharmacoepidemiol Drug Saf. 2020 Apr;29(4):453-460. doi: 10.1002/pds.4947. Epub 2020 Feb 11.
Published epidemiological studies on the association between finasteride use and the risk of male breast cancer have been inconclusive due to methodological limitations including a few male breast cancer cases included. Determinants of male breast cancer have been studied, but it remains unexplored whether these are also related to finasteride use and thereby constitute potential confounders. This study aimed to assess whether there are differences between finasteride users and nonusers with regard to numerous potential confounders.
In total, 246 508 finasteride users (≥35 years) were identified in the prescription registries of Denmark (1995-2014), Finland (1997-2013), and Sweden (2005-2014). An equal number of nonusers were sampled. The directed acyclic graph (DAG) methodology was used to identify potential confounders for the association between finasteride and male breast cancer. A logistic regression model compared finasteride users and nonusers with regard to potential confounders that were measurable in registries and population surveys.
Finasteride users had higher odds of testicular abnormalities (odds ratio [OR] 1.40; 95% confidence interval [CI] 1.36-1.44), obesity (1.31; 1.23-1.39), exogenous testosterone (1.61; 1.48-1.74), radiation exposure (1.22; 1.18-1.27), and diabetes (1.07; 1.04-1.10) and lower odds of occupational exposure in perfume industry or in high temperature environments (0.93; 0.87-0.99), living alone (0.89; 0.88-0.91), living in urban/suburban areas (0.97; 0.95-0.99), and physical inactivity (0.70; 0.50-0.99) compared to nonusers.
Systematic differences between finasteride users and nonusers were found emphasizing the importance of confounder adjustment of associations between finasteride and male breast cancer.
由于方法学上的局限性,包括纳入了少数男性乳腺癌病例,已发表的关于非那雄胺使用与男性乳腺癌风险之间关联的流行病学研究结果尚无定论。男性乳腺癌的决定因素已经得到研究,但仍不清楚这些因素是否也与非那雄胺的使用有关,从而构成潜在的混杂因素。本研究旨在评估在许多潜在混杂因素方面,非那雄胺使用者与非使用者之间是否存在差异。
在丹麦(1995-2014 年)、芬兰(1997-2013 年)和瑞典(2005-2014 年)的处方登记处共确定了 246508 名非那雄胺使用者(≥35 岁)。按照人数相等的原则抽取了非使用者。使用有向无环图(DAG)方法确定非那雄胺与男性乳腺癌之间关联的潜在混杂因素。使用逻辑回归模型比较了登记处和人群调查中可测量的潜在混杂因素在非那雄胺使用者和非使用者之间的差异。
非那雄胺使用者睾丸异常的可能性更高(比值比 [OR] 1.40;95%置信区间 [CI] 1.36-1.44)、肥胖(1.31;1.23-1.39)、外源性睾酮(1.61;1.48-1.74)、辐射暴露(1.22;1.18-1.27)和糖尿病(1.07;1.04-1.10),而从事香水行业或处于高温环境中的职业暴露(0.93;0.87-0.99)、独居(0.89;0.88-0.91)、居住在城市/郊区(0.97;0.95-0.99)和缺乏体育锻炼(0.70;0.50-0.99)的可能性更低。
与非使用者相比,非那雄胺使用者和非使用者之间存在系统性差异,这强调了在非那雄胺与男性乳腺癌之间的关联中调整混杂因素的重要性。